CMP

0.00%

26.0¢ compumedics limited

The other thing that this new FDA approval will do is put us in...

First 6 Last

Fingers xed

7,570 Posts.

950

17/02/20

19:59

Post #: 42982199

Originally posted by Fingers xed: ↑
Will be after this Pac Partners report
COMPANY Compumedics (CMP)
RECOMMENDATION Buy | PT $1.40/share (+47%) | High Risk
EVENT FDA approval for MEG | Some blue sky is delivered
KEY POINTS
·US FDA approval for CMP’s new generation brain wave scanner makes tripling of EBITDA to $24m within three years more tangible. This helps CMP’s EV/EBITDA reduce from 20.7x to 5.8x.
·In operational terms, CMP can double the FY’20F EBITDA of $7.3m from selling 2,000 premium sleep and brain diagnostic devices at $20,000 with just three new brain scanners @ $5,000,000 each.
·Two main hurdles for this new brain scanner (MEG) are cleared: One – Win major contract vs. global peer (and see it retire); and, Two – Today’s FDA validation which allows reimbursement to start.
· We stay with our forecast of a significant ramp-up over three years to EBITDA of $24m, with 30% from Base and 70% from Step-outs (MEG, eHealth/Somfit)
·CMP reiterated its FY’20 EBITDA target of $6.5m to $7.5m in January 2020 without any contribution from MEG. Around 80% of the EBITDA is likely to come in 2H. CMP reports on 25 February.
FY’21F METRICS PER 16.6x | EV/EBITDA 11.4x | Yield 1.5%
LINK TO RESEARCH REPORTRR_CMP_200218 (8 pages)
CMP MANAGEMENT AT PAC PARTNERS OFFICE
Melbourne – Tuesday 24 March – 12:30pm
Sydney– Wednesday 25 March – 12:30pm
INVESTMENT VIEW
We retain a Buy on CMP and expect it to re-rate towards 12 Month Price Target of $1.40/share (+47% today) with:
Base (sleep & neuro diagnostic devices & services) deliver reliable growth with the dual premium and mid offers, and eHealth moves into growth leverage after the USA backbone build.
Blue sky from Step-outs becoming more tangible with new orders of MEG in 2H’20F with US FDA approval granted today, and a distribution partner for SomFit which we expect by end CY2020.
Expand
The other thing that this new FDA approval will do is put us in the spotlight for a possible take over by bigger players in the USA .

CMP Price at posting: 88.0¢ Sentiment: Buy Disclosure: Held

4 Upvote

0 Great analysis

There are more pages in this discussion • 9 more messages in this thread...

First 6 Last

Add CMP (ASX) to my watchlist

(20min delay)
Last 26.0¢		Change 0.000(0.00%)		Mkt cap ! $46.06M

Open	High	Low	Value	Volume
26.0¢	26.0¢	26.0¢	$2.984K	11.47K

Buyers (Bids)

No.	Vol.	Price($)
1	2724	26.0¢

Sellers (Offers)

Price($)	Vol.	No.
29.0¢	10000	1

View Market Depth

No.	Vol.	Price($)
1	2724	0.260
1	14000	0.235
1	4444	0.225
2	18181	0.220
1	13900	0.215

Price($)	Vol.	No.
0.290	10000	1
0.295	6750	1
0.300	35865	2
0.315	19000	1
0.350	5365	1

Last trade - 13.55pm 06/05/2024 (20 minute delay)

CMP (ASX) Chart

The other thing that this new FDA approval will do is put us in...

Featured News

Tamboran is listing on the NYSE, and Wall Street is paying attention

Mantle Minerals to kick off drilling at Mt Berghaus in WA

Westpac tracks lower in profits in first half of 2024, with a 16% yoy drop amid slowing economy

Sold out signs go up for RIU Resources Roundup in Sydney

Maiden drilling at West Arunta hints at major IOCG system for Rincon

Buyers (Bids)

Sellers (Offers)

Featured News

COMPANY Compumedics (CMP)
RECOMMENDATION Buy \| PT $1.40/share (+47%) \| High Risk
EVENT FDA approval for MEG \| Some blue sky is delivered
KEY POINTS
·US FDA approval for CMP’s new generation brain wave scanner makes tripling of EBITDA to $24m within three years more tangible. This helps CMP’s EV/EBITDA reduce from 20.7x to 5.8x.
·In operational terms, CMP can double the FY’20F EBITDA of $7.3m from selling 2,000 premium sleep and brain diagnostic devices at $20,000 with just three new brain scanners @ $5,000,000 each.
·Two main hurdles for this new brain scanner (MEG) are cleared: One – Win major contract vs. global peer (and see it retire); and, Two – Today’s FDA validation which allows reimbursement to start.
· We stay with our forecast of a significant ramp-up over three years to EBITDA of $24m, with 30% from Base and 70% from Step-outs (MEG, eHealth/Somfit)
·CMP reiterated its FY’20 EBITDA target of $6.5m to $7.5m in January 2020 without any contribution from MEG. Around 80% of the EBITDA is likely to come in 2H. CMP reports on 25 February.
FY’21F METRICS PER 16.6x \| EV/EBITDA 11.4x \| Yield 1.5%
LINK TO RESEARCH REPORTRR_CMP_200218 (8 pages)
CMP MANAGEMENT AT PAC PARTNERS OFFICE
Melbourne – Tuesday 24 March – 12:30pm
Sydney– Wednesday 25 March – 12:30pm
INVESTMENT VIEW
We retain a Buy on CMP and expect it to re-rate towards 12 Month Price Target of $1.40/share (+47% today) with: Base (sleep & neuro diagnostic devices & services) deliver reliable growth with the dual premium and mid offers, and eHealth moves into growth leverage after the USA backbone build. Blue sky from Step-outs becoming more tangible with new orders of MEG in 2H’20F with US FDA approval granted today, and a distribution partner for SomFit which we expect by end CY2020.

The other thing that this new FDA approval will do is put us in...

Featured News

Top Stories

Tamboran is listing on the NYSE, and Wall Street is paying attention

Mantle Minerals to kick off drilling at Mt Berghaus in WA

Westpac tracks lower in profits in first half of 2024, with a 16% yoy drop amid slowing economy

Sold out signs go up for RIU Resources Roundup in Sydney

Maiden drilling at West Arunta hints at major IOCG system for Rincon

Buyers (Bids)

Sellers (Offers)

Featured News